NCT06827080

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Zhengguo Chen · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.

Conditions

• Metastatic Castration-resistant Prostate Cancer, MCRPC
• Cancer

Interventions

Type	Name	Description
DRUG	30 mCi NYMO32	The initial dose is set at 30 mCi.
DRUG	50 mCi NYMO32	The dose will be escalated to 50 mCi.
DRUG	80 mCi NYMO32	The dose will be escalated to 80 mCi.
DRUG	130 mCi NYMO32	The dose will be escalated to 130 mCi.
DRUG	200 mCi NYMO32	The maximum dose is set at 200 mCi.

Timeline

• Start date: 2025-02-11
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-02-14
• Last updated: 2025-02-14

Regulatory

• FDA-regulated drug study